This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why You Should Hold Molina Healthcare (MOH) in Your Portfolio
by Zacks Equity Research
Molina Healthcare (MOH) remains well-poised for growth on the back of a growing customer base within its Government business. Acquisitions and cost-saving measures also aid the health insurer.
Here's How Much You'd Have If You Invested $1000 in Idexx Laboratories a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Why Idexx (IDXX) Could Beat Earnings Estimates Again
by Zacks Equity Research
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
IDEXX (IDXX) Aided by Global Growth, Solid Instrument Placement
by Zacks Equity Research
IDEXX's (IDXX) rapid assay revenue growth is supported by solid volume gains in the United States and benefits from net price increases.
5 Stocks Powering Nasdaq ETF to Start 2023
by Sweta Killa
The rally has been broad-based. And the high beta and high growth sector took charge, with the tech-heavy Nasdaq Composite Index rising 5.1% in the initial two weeks of 2023.
Here's Why You Should Invest in IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) owing to strong international growth.
IDEXX (IDXX) CAG Sales Growth Strong, Costs Continue to Rise
by Zacks Equity Research
IDEXX's (IDXX) international revenues are primarily aided by gains in CAG and Water businesses.
Avanos Medical (AVNS) Up 21% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IDEXX (IDXX) Q3 Earnings Beat Estimates, 2022 EPS View Down
by Zacks Equity Research
IDEXX's (IDXX) Q3 top-line performance rides on strong CAG Diagnostics recurring revenue growth.
Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 5.39% and 1.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks Due to Report Earnings on Nov 1: MCK, CTLT & More
by Debanjana Dey
MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, CTLT, ECL, ABMD, HSIC and IDXX are placed ahead of their earnings releases.
Nevro (NVRO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pet Industry Seems Recession-Proof: ETF & Stocks in Focus
by Sanghamitra Saha
American Pet Products Association, 70% of U.S. households own a pet, as quoted on Yahoo Finance. And Americans are splurging on their pets despite high inflation.
IDEXX (IDXX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
IDEXX's (IDXX) CAG premium instrument placements are expected to have recorded significant growth in Q3 on the continued rise in Catalyst and premium hematology placements.
Why Is Idexx (IDXX) Down 14.6% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
OCPNY vs. IDXX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
OCPNY vs. IDXX: Which Stock Is the Better Value Option?
IDEXX (IDXX) Suffers From Macro Headwinds, Cost Constraints
by Zacks Equity Research
The strengthening of the rate of exchange for the U.S. dollar relative to other currencies has a negative impact on IDEXX's (IDXX) revenues.
IDEXX (IDXX) Q2 Earnings Surpass Estimates, 2022 View Down
by Zacks Equity Research
IDEXX's (IDXX) Q2 top-line benefits from strong sales at the CAG and Water businesses.
Idexx Laboratories (IDXX) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 1.30% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Quotient (QTNT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OCPNY or IDXX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OCPNY vs. IDXX: Which Stock Is the Better Value Option?
3 MedTech Stocks That are Likely to Beat This Earnings Season
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how STE, TMO and IDXX are poised ahead of their earnings releases.
IDEXX (IDXX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
IDEXX's (IDXX) Q2 performance will likely benefit from strong sales from the CAG Diagnostics and Water businesses.
Idexx Laboratories (IDXX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.